Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of IMP9064 alone and in combination in advanced solid tumors
CTR20221315Phase 2Active
- Sponsor
- IMPACT Therapeutics
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IMP9064 in Nonhematologic neoplasms, sponsored by IMPACT Therapeutics. Started Jul 2022; status: active.
02
Drugs
IMP9064
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20221315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221315.